![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration
|
|
|
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy.
Washington DC, USA, 26-28 May 2015
Oral Presentation #3
Emi Tafoya, Yasong Lu , Melody Luo, Premkumar Narasimhan, Neelima Thanneer, Brenda Cirincione, Timothy Eley, Nannan Zhou, Dennis Hernandez, Fiona McPhee, Tarek Leil
Bristol-Myers Squibb, Princeton, NJ, USA; Bristol-Myers Squibb, Wallingford, CT, USA
![Pharm1.gif](../images/052915/052915-15/Pharm1.gif)
![Pharm2.gif](../images/052915/052915-15/Pharm2.gif)
![Pharm3.gif](../images/052915/052915-15/Pharm3.gif)
![Pharm4.gif](../images/052915/052915-15/Pharm4.gif)
EASL: Sofosbuvir Plus Peg-IFN/RBV for 12 Weeks vs Sofosbuvir/RBV for 16 or 24 Weeks in Genotype 3 HCV-Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study - (04/27/15)
![Pharm5.gif](../images/052915/052915-15/Pharm5.gif)
![Pharm6.gif](../images/052915/052915-15/Pharm6.gif)
![Pharm7.gif](../images/052915/052915-15/Pharm7.gif)
![Pharm8.gif](../images/052915/052915-15/Pharm8.gif)
![Pharm9.gif](../images/052915/052915-15/Pharm9.gif)
![Pharm10.gif](../images/052915/052915-15/Pharm10.gif)
![Pharm11.gif](../images/052915/052915-15/Pharm11.gif)
![Pharm12.gif](../images/052915/052915-15/Pharm12.gif)
![Pharm13.gif](../images/052915/052915-15/Pharm13.gif)
![Pharm14.gif](../images/052915/052915-15/Pharm14.gif)
![Pharm15.gif](../images/052915/052915-15/Pharm15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|